Anticancer Activity of New Bis-(3-(Thiophen-2-yl)-1H-Pyrazol-4-yl)Chalcones: Synthesis, in-Silico, and in-Vitro Studies

References

• A. H. Abadi, A. A. H. Eissa, and G. S. Hassan, “Synthesis of Novel 1,3,4-Trisubstituted Pyrazole Derivatives and Their Evaluation as Antitumor and Antiangiogenic Agents,” Chemical & Pharmaceutical Bulletin 51, no. 7 (2003): 838–44. doi:10.1248/cpb.51.838.
   PubMed Web of Science ®Google Scholar
• P. G. Baraldi, I. Beria, P. Cozzi, C. Geroni, A. Espinosa, M. A. Gallo, A. Entrena, J. P. Bingham, J. A. Hartley, and R. Romagnoli, “Cinnamoyl Nitrogen Mustard Derivatives of Pyrazole Analogues of Tallimustine Modified at the Amidino Moiety: design, Synthesis, Molecular Modeling and Antitumor Activity Studies,” Bioorganic & Medicinal Chemistry 12, no. 14 (2004): 3911–21. doi:10.1016/j.bmc.2004.04.045.
   PubMed Web of Science ®Google Scholar
• I. Bouabdallah, L. A. M’Barek, A. Zyad, A. Ramdani, I. Zidane, and A. Melhaoui, “Anticancer Effect of Three Pyrazole Derivatives,” Natural Product Research 20, no. 11 (2006): 1024–30. doi:10.1080/14786410600921441.
   PubMed Web of Science ®Google Scholar
• K.-M J. Cheung, T. P. Matthews, K. James, M. G. Rowlands, K. J. Boxall, S. Y. Sharp, A. Maloney, S. M. Roe, C. Prodromou, L. H. Pearl, et al, “The Identification, Synthesis, Protein Crystal Structure and in Vitro Biochemical Evaluation of a New 3,4-Diarylpyrazole Class of Hsp90 Inhibitors,” Bioorganic & Medicinal Chemistry Letters 15, no. 14 (2005): 3338–43. doi:10.1016/j.bmcl.2005.05.046.
   PubMed Web of Science ®Google Scholar
• H. Ohki, K. Hirotani, H. Naito, S. Ohsuki, M. Minami, A. Ejima, Y. Koiso, and Y. Hashimoto, “Synthesis and Mechanism of Action of Novel Pyrimidinyl Pyrazole Derivatives Possessing Antiproliferative Activity,” Bioorganic & Medicinal Chemistry Letters 12, no. 21 (2002): 3191–3. doi:10.1016/S0960-894X(02)00568-1.
   PubMed Web of Science ®Google Scholar
• B. Kocyigit-Kaymakcioglu, R. G. Aker, K. Tezcan, E. Sakalli, S. Ketenci, E. E. Oruç-Emre, D. Akin, A. Gurbanova, B. Terzioglu, F. Onat, et al, “Anticonvulsant Activity of 3,5-Dimethylpyrazole Derivatives in Animal Models,” Medicinal Chemistry Research 20, no. 5 (2011): 607–14., doi:10.1007/s00044-010-9358-6.
   Web of Science ®Google Scholar
• D. Kaushik, S. A. Khan, G. Chawla, and S. Kumar, “N'-[(5-Chloro-3-Methyl-1-Phenyl-1H-Pyrazol-4-yl)Methylene] 2/4-Substituted Hydrazides: synthesis and Anticonvulsant Activity,” European Journal of Medicinal Chemistry 45, no. 9 (2010): 3943–9. doi:10.1016/j.ejmech.2010.05.049.
   PubMed Web of Science ®Google Scholar
• A. Tanitame, Y. Oyamada, K. Ofuji, M. Fujimoto, K. Suzuki, T. Ueda, H. Terauchi, M. Kawasaki, K. Nagai, M. Wachi, et al, “Synthesis and Antibacterial Activity of Novel and Potent DNA Gyrase Inhibitors with Azole Ring,” Bioorganic & Medicinal Chemistry 12, no. 21 (2004): 5515–24. doi:10.1016/j.bmc.2004.08.010.
   PubMed Web of Science ®Google Scholar
• J. Finn, K. Mattia, M. Morytko, S. Ram, Y. Yang, X. Wu, E. Mak, P. Gallant, and D. Keith, “Discovery of a Potent and Selective Series of Pyrazole Bacterial Methionyl-tRNA Synthetase Inhibitors,” Bioorganic & Medicinal Chemistry Letters 13, no. 13 (2003): 2231–4. doi:10.1016/S0960-894X(03)00298-1.
   PubMed Web of Science ®Google Scholar
• D. Zampieri, M. G. Mamolo, E. Laurini, G. Scialino, E. Banfi, and L. Vio, “Antifungal and Antimycobacterial Activity of 1-(3,5-Diaryl-4,5-Dihydro-1H-Pyrazol-4-yl)-1H-Imidazole Derivatives,” Bioorganic & Medicinal Chemistry 16, no. 8 (2008): 4516–22. doi:10.1016/j.bmc.2008.02.055.
   PubMed Web of Science ®Google Scholar
• Y. Li, H.-Q. Zhang, J. Liu, X.-P. Yang, and Z.-J. Liu, “Stereoselective Synthesis and Antifungal Activities of (E)-Alpha-(Methoxyimino)Benzeneacetate Derivatives Containing 1,3,5-Substituted Pyrazole Ring,” Journal of Agricultural and Food Chemistry 54, no. 10 (2006): 3636–40. doi:10.1021/jf060074f.
   PubMed Web of Science ®Google Scholar
• P. N. Kalaria, S. P. Satasia, and D. K. Raval, “Synthesis, Characterization and Pharmacological Screening of Some Novel 5-Imidazopyrazole Incorporated Polyhydroquinoline Derivatives,” European Journal of Medicinal Chemistry 78 (2014): 207–16. doi:10.1016/j.ejmech.2014.02.015.
   PubMed Web of Science ®Google Scholar
• A. A. Bekhit, A. Hymete, H. Asfaw, and A. E.-D A. Bekhit, “Synthesis and Biological Evaluation of Some Pyrazole Derivatives as anti-Malarial Agents,” Archiv der Pharmazie 345, no. 2 (2012): 147–54. doi:10.1002/ardp.201100078.
   PubMed Web of Science ®Google Scholar
• A. A. Bekhit, and H. T. Y. Fahmy, “Design and Synthesis of Some Substituted 1H-Pyrazolyl-Oxazolidines or 1H-Pyrazolyl-Thiazolidines as anti-Inflammatory-Antimicrobial Agents,” Archiv der Pharmazie 336, no. 2 (2003): 111–8. doi:10.1002/ardp.200390007.
   PubMed Web of Science ®Google Scholar
• N. Siddiqui, P. Alam, and W. Ahsan, “Design, Synthesis, and in-Vivo Pharmacological Screening of N,3-(Substituted Diphenyl)-5-Phenyl-1H-Pyrazoline-1-Carbothioamide Derivatives,” Archiv der Pharmazie 342, no. 3 (2009): 173–81. doi:10.1002/ardp.200900002.
   PubMed Web of Science ®Google Scholar
• E. Palaska, F. Aydin, G. Uçar, and D. Erol, “Synthesis and Monoamine Oxidase Inhibitory Activities of 1-Thiocarbamoyl-3,5-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives,” Archiv der Pharmazie 341, no. 4 (2008): 209–15. doi:10.1002/ardp.200700159.
   PubMed Web of Science ®Google Scholar
• R. Mulder, K. Wellinga, and J. J. van Daalen, “A New Class of Insecticides,” Die Naturwissenschaften 62, no. 11 (1975): 531–2. doi:10.1007/BF00609070.
   PubMedGoogle Scholar
• B. K. Srivastava, R. Soni, J. Z. Patel, A. Joharapurkar, N. Sadhwani, S. Kshirsagar, B. Mishra, V. Takale, S. Gupta, P. Pandya, et al, “Hair Growth Stimulator Property of Thienyl Substituted Pyrazole Carboxamide Derivatives as a CB1 Receptor Antagonist with in Vivo Antiobesity Effect,” Bioorganic & Medicinal Chemistry Letters 19, no. 9 (2009): 2546–50. doi:10.1016/j.bmcl.2009.03.046.
   PubMed Web of Science ®Google Scholar
• B. F. Abdel-Wahab, H. Abdel-Gawad, G. E. A. Awad, and F. A. Badria, “Synthesis, Antimicrobial, Antioxidant, anti-Inflammatory, and Analgesic Activities of Some New 3-(2′-Thienyl)Pyrazole-Based Heterocycles,” Medicinal Chemistry Research 21, no. 7 (2012): 1418–26. doi:10.1007/s00044-011-9661-x.
   Web of Science ®Google Scholar
• S. R. Lemes, C. R. eSilva, J. H. Véras, L. Chen-Chen, R. S. Lima, C. N. Perez, M. A. Montes de Sousa, P. R. de Melo Reis, and N. J. da Silva Junior, “Presence of Antigenotoxic and Anticytotoxic Effects of the Chalcone 1E,4E-1-(4-Chlorophenyl)-5-(2,6,6-Trimethylcyclohexen-1-yl)Penta-1,4-Dien-3-One Using in Vitro and in Vivo Assays,” Drug and Chemical Toxicology 43, no. 4 (2020): 383–90. doi:10.1080/01480545.2018.1497046.
   PubMed Web of Science ®Google Scholar
• S. Rana, E. C. Blowers, C. Tebbe, J. I. Contreras, P. Radhakrishnan, S. Kizhake, T. Zhou, R. N. Rajule, J. L. Arnst, A. R. Munkarah, et al, “Isatin Derived Spirocyclic Analogues with α-Methylene-γ-Butyrolactone as Anticancer Agents: A Structure-Activity Relationship Study,” Journal of Medicinal Chemistry 59, no. 10 (2016): 5121–7. doi:10.1021/acs.jmedchem.6b00400.
   PubMed Web of Science ®Google Scholar
• L. Heller, S. Schwarz, V. Perl, A. Köwitsch, B. Siewert, and R. Csuk, “Incorporation of a Michael Acceptor Enhances the Antitumor Activity of Triterpenoic Acids,” European Journal of Medicinal Chemistry 101 (2015): 391–9. doi:10.1016/j.ejmech.2015.07.004.
   PubMed Web of Science ®Google Scholar
• S. M. Raja, R. J. Clubb, C. Ortega-Cava, S. H. Williams, T. A. Bailey, L. Duan, X. Zhao, A. L. Reddi, A. M. Nyong, A. Natarajan, et al, “Anticancer Activity of Celastrol in Combination with ErbB2-Targeted Therapeutics for Treatment of ErbB2-Overexpressing Breast Cancers,” Cancer Biology & Therapy 11, no. 2 (2011): 263–76. doi:10.4161/cbt.11.2.13959.
   PubMed Web of Science ®Google Scholar
• M. Gersch, J. Kreuzer, and S. A. Sieber, “Electrophilic Natural Products and Their Biological Targets,” Natural Product Reports 29, no. 6 (2012): 659–82. doi:10.1039/c2np20012k.
   PubMed Web of Science ®Google Scholar
• M. Zhu, J. Wang, J. Xie, L. Chen, X. Wei, X. Jiang, M. Bao, Y. Qiu, Q. Chen, W. Li, et al, “Design, Synthesis, and Evaluation of Chalcone Analogues Incorporate α,β-Unsaturated Ketone Functionality as anti-Lung Cancer Agents via Evoking ROS to Induce Pyroptosis,” European Journal of Medicinal Chemistry 157 (2018): 1395–405. doi:10.1016/j.ejmech.2018.08.072.
   PubMed Web of Science ®Google Scholar
• P. A. Jackson, J. C. Widen, D. A. Harki, and K. M. Brummond, “Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions,” Journal of Medicinal Chemistry 60, no. 3 (2017): 839–85. doi:10.1021/acs.jmedchem.6b00788.
   PubMed Web of Science ®Google Scholar
• Y. Li, L.-P. Zhang, F. Dai, W.-J. Yan, H.-B. Wang, Z.-S. Tu, and B. Zhou, “Hexamethoxylated Monocarbonyl Analogues of Curcumin Cause G2/M Cell Cycle Arrest in NCI-H460 Cells via Michael Acceptor-Dependent Redox Intervention,” Journal of Agricultural and Food Chemistry 63, no. 35 (2015): 7731–42. doi:10.1021/acs.jafc.5b02011.
   PubMed Web of Science ®Google Scholar
• A. A. Bekhit, and T. Abdel-Aziem, “Design, Synthesis and Biological Evaluation of Some Pyrazole Derivatives as anti-Inflammatory-Antimicrobial Agents,” Bioorganic & Medicinal Chemistry 12, no. 8 (2004): 1935–45. doi:10.1016/j.bmc.2004.01.037.
   PubMed Web of Science ®Google Scholar
• B. P. Bandgar, S. S. Gawande, R. G. Bodade, N. M. Gawande, and C. N. Khobragade, “Synthesis and Biological Evaluation of a Novel Series of Pyrazole Chalcones as anti-Inflammatory, Antioxidant and Antimicrobial Agents,” Bioorganic & Medicinal Chemistry 17, no. 24 (2009): 8168–73. doi:10.1016/j.bmc.2009.10.035.
   PubMed Web of Science ®Google Scholar
• L. Pan, H. Becker, and C. Gerhäuser, “Xanthohumol Induces Apoptosis in Cultured 40-16 Human Colon Cancer Cells by Activation of the Death Receptor- and Mitochondrial Pathway,” Molecular Nutrition & Food Research 49, no. 9 (2005): 837–43. doi:10.1002/mnfr.200500065.
   PubMed Web of Science ®Google Scholar
• C. Karthikeyan, N. S. H. Narayana Moorthy, S. Ramasamy, U. Vanam, E. Manivannan, D. Karunagaran, and P. Trivedi, “Advances in Chalcones with Anticancer Activities,” Recent Patents on anti-Cancer Drug Discovery 10, no. 1 (2015): 97–115. doi:10.2174/1574892809666140819153902.
   PubMed Web of Science ®Google Scholar
• S. Lust, B. Vanhoecke, A. Janssens, J. Philippe, M. Bracke, and F. Offner, “Xanthohumol Kills B-Chronic Lymphocytic Leukemia Cells by an Apoptotic Mechanism,” Molecular Nutrition & Food Research 49, no. 9 (2005): 844–50. doi:10.1002/mnfr.200500045.
   PubMed Web of Science ®Google Scholar
• C. C. Yit, and N. P. Das, “Cytotoxic Effect of Butein on Human Colon Adenocarcinoma Cell Proliferation,” Cancer Letters 82, no. 1 (1994): 65–72. doi:10.1016/0304-3835(94)90147-3.
   PubMed Web of Science ®Google Scholar
• X. Zi, and A. R. Simoneau, “Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice,” Cancer Research 65, no. 8 (2005): 3479–86. doi:10.1158/0008-5472.CAN-04-3803.
   PubMed Web of Science ®Google Scholar
• F. Chimenti, R. Fioravanti, A. Bolasco, P. Chimenti, D. Secci, F. Rossi, M. Yáñez, F. Orallo, F. Ortuso, and S. Alcaro, “Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors,” Journal of Medicinal Chemistry 52, no. 9 (2009): 2818–24. doi:10.1021/jm801590u.
   PubMed Web of Science ®Google Scholar
• E. M. Fathi, F. M. Sroor, K. F. Mahrous, M. F. Mohamed, K. Mahmoud, M. Emara, A. H. M. Elwahy, and I. A. Abdelhamid, “Design, Synthesis, in Silico and in Vitro Anticancer Activity of Novel Bis‐Furanyl‐Chalcone Derivatives Linked through Alkyl Spacers,” ChemistrySelect 6, no. 24 (2021): 6202–11. doi:10.1002/slct.202100884.
   Web of Science ®Google Scholar
• F. M. Sroor, M. M. Aboelenin, K. F. Mahrous, K. Mahmoud, A. H. M. Elwahy, and I. A. Abdelhamid, “Novel 2‐Cyanoacrylamido‐4,5,6,7‐Tetrahydrobenzo[ b ]Thiophene Derivatives as Potent Anticancer Agents,” Archiv Der Pharmazie 353, no. 10 (2020): 2000069. doi:10.1002/ardp.202000069.
   PubMed Web of Science ®Google Scholar
• M. F. Mohamed, F. M. Sroor, N. S. Ibrahim, G. S. Salem, H. H. El-Sayed, M. M. Mahmoud, M.-A M. Wagdy, A. M. Ahmed, A.-A T. Mahmoud, S. S. Ibrahim, et al, “Novel [l,2,4]Triazolo[3,4-a]Isoquinoline Chalcones as New Chemotherapeutic Agents: Block IAP Tyrosine Kinase Domain and Induce Both Intrinsic and Extrinsic Pathways of Apoptosis,” Investigational New Drugs 39, no. 1 (2021): 98–110. doi:10.1007/s10637-020-00987-2.
   PubMed Web of Science ®Google Scholar
• S. Shafi, M. Mahboob Alam, N. Mulakayala, C. Mulakayala, G. Vanaja, A. M. Kalle, R. Pallu, and M. S. Alam, “Synthesis of Novel 2-Mercapto Benzothiazole and 1,2,3-Triazole Based Bis-Heterocycles: their anti-Inflammatory and anti-Nociceptive Activities,” European Journal of Medicinal Chemistry 49 (2012): 324–33. doi:10.1016/j.ejmech.2012.01.032.
   PubMed Web of Science ®Google Scholar
• A. Muralikrishna, B. C. Venkatesh, V. Padmavathi, A. Padmaja, P. Kondaiah, and N. S. Krishna, “Synthesis, Antimicrobial and Cytotoxic Activities of Sulfone Linked Bis Heterocycles,” European Journal of Medicinal Chemistry 54 (2012): 605–14. doi:10.1016/j.ejmech.2012.06.014.
   PubMed Web of Science ®Google Scholar
• V. Padmavathi, P. Thriveni, G. Sudhakar Reddy, and D. Deepti, “Synthesis and Antimicrobial Activity of Novel Sulfone-Linked Bis Heterocycles,” European Journal of Medicinal Chemistry 43, no. 5 (2008): 917–24. doi:10.1016/j.ejmech.2007.06.011.
   PubMed Web of Science ®Google Scholar
• M. F. Mohamed, A. F. Darweesh, A. H. M. Elwahy, and I. A. Abdelhamid, “Synthesis, Characterization and Antitumor Activity of Novel Tetrapodal 1,4-Dihydropyridines: p53 Induction, Cell Cycle Arrest and Low Damage Effect on Normal Cells Induced by Genotoxic Factor H 2 O 2,” RSC Advances 6, no. 47 (2016): 40900–10. doi:10.1039/C6RA04974E.
   Web of Science ®Google Scholar
• M. F. Mohamed, M. S. Mohamed, S. A. Shouman, M. M. Fathi, and I. A. Abdelhamid, “Synthesis and Biological Evaluation of a Novel Series of Chalcones Incorporated Pyrazole Moiety as Anticancer and Antimicrobial Agents,” Applied Biochemistry and Biotechnology 168, no. 5 (2012): 1153–62. doi:10.1007/s12010-012-9848-8.
   PubMed Web of Science ®Google Scholar
• F. M. Sroor, A. M. Othman, M. A. Tantawy, K. F. Mahrous, and M. E. El-Naggar, “Synthesis, Antimicrobial, anti-Cancer and in Silico Studies of New Urea Derivatives,” Bioorganic Chemistry 112 (2021): 104953. doi:10.1016/j.bioorg.2021.104953.
   PubMed Web of Science ®Google Scholar
• M. A. Tantawy, F. M. Sroor, M. F. Mohamed, M. E. El-Naggar, F. M. Saleh, H. M. Hassaneen, and I. A. Abdelhamid, “Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer,” Anti-Cancer Agents in Medicinal Chemistry 20, no. 1 (2020): 70–83. doi:10.2174/1871520619666191024121116.
   PubMed Web of Science ®Google Scholar
• F. M. Sroor, T. K. Khatab, W. M. Basyouni, and K. A. M. El-Bayouki, “Synthesis and Molecular Docking Studies of Some New Thiosemicarbazone Derivatives as HCV Polymeraseinhibitors,” Synthetic Communications 49, no. 11 (2019): 1444–56. doi:10.1080/00397911.2019.1605443.
   Web of Science ®Google Scholar
• F. M. Sroor, W. M. Basyouni, W. M. Tohamy, T. H. Abdelhafez, and M. K. El-Awady, “Novel Pyrrolo[2,3-d]Pyrimidine Derivatives: Design, Synthesis, Structure Elucidation and in Vitro anti-BVDV Activity,” Tetrahedron 75, no. 51 (2019): 130749. doi:10.1016/j.tet.2019.130749.
   Web of Science ®Google Scholar
• F. M. Sroor, A. M. Abdelmoniem, and I. A. Abdelhamid, “Facile Synthesis, Structural Activity Relationship, Molecular Modeling and in Vitro Biological Evaluation of New Urea Derivatives with Incorporated Isoxazole and Thiazole Moieties as Anticancer Agents,” ChemistrySelect 4, no. 34 (2019): 10113–21. doi:10.1002/slct.201901415.
   Web of Science ®Google Scholar
• F. M. Sroor, W. M. Basyouni, H. F. Aly, S. A. Ali, and A. F. Arafa, Medicinal Chemistry Research 31 (2022): 195-206. doi:10.1007/s00044-021-02829-z.
   Google Scholar
• M. T. Helmy, F. M. Sroor, K. F. Mahrous, K. Mahmoud, H. M. Hassaneen, F. M. Saleh, I. A. Abdelhamid, and M. A. Mohamed Teleb, Archiv der Pharmazie 355 (2022): 2100381. doi:10.1002/ardp.202100381.
   PubMedGoogle Scholar
• M. F. Mohamed, H. M. Hassaneen, and I. A. Abdelhamid, “Cytotoxicity, Molecular Modeling, Cell Cycle Arrest, and Apoptotic Induction Induced by Novel Tetrahydro-[1,2,4]Triazolo[3,4-a]Isoquinoline Chalcones,” European Journal of Medicinal Chemistry 143 (2018): 532–41. doi:10.1016/j.ejmech.2017.11.045.
   PubMed Web of Science ®Google Scholar
• A. M. Abdelmoniem, T. A. Salaheldin, I. A. Abdelhamid, and A. H. M. Elwahy, “New Bis(Dihydropyridine-3,5-Dicarbonitrile) Derivatives: Green Synthesis and Cytotoxic Activity Evaluation,” Journal of Heterocyclic Chemistry 54, no. 5 (2017): 2670–7. doi:10.1002/jhet.2867.
   Web of Science ®Google Scholar
• A. Elwahy, I. Abdelhamid, and H. Diab, “ZnO-Nanoparticles-Catalyzed Synthesis of Poly(Tetrahydrobenzimidazo[2,1-b]Quinazolin-1(2H)-Ones) as Novel Multi-Armed Molecules,” Synlett 29, no. 12 (2018): 1627–33. doi:10.1055/s-0037-1609967.
   Web of Science ®Google Scholar
• A. Elwahy, and M. Shaaban, “Synthesis of Trifluoromethyl-Substituted Fused Bicyclic Heterocycles and Their Corresponding Benzo-Fused Analogues,” Current Organic Synthesis 7, no. 5 (2010): 433–54. doi:10.2174/157017910792246117.
   Web of Science ®Google Scholar
• A. H. M. Elwahy, and A. A. Abbas, “Bis(β-Difunctional) Compounds: Versatile Starting Materials for Novel Bis(Heterocycles),” Synthetic Communications 30, no. 16 (2000): 2903–21. doi:10.1080/00397910008087441.
   Web of Science ®Google Scholar
• M. G. Kamel, F. M. Sroor, A. M. Othman, K. F. Mahrous, F. M. Saleh, H. M. Hassaneen, T. A. Abdallah, I. A. Abdelhamid, and M. A. M. Teleb, Monatshefte für Chemie - Chemical Monthly 153 (2022): 211-221. doi:10.1007/s00706-021-02886-5.
   Google Scholar
• F. M. Sroor, A. M. Othman, M. M. Aboelenin, and K. F. Mahrous, Medicinal Chemistry Research 31 (2022): 400-415. doi:10.1007/s00044-022-02849-3.
   Google Scholar
• F. M. Sroor, S. Y. Abbas, W. M. Basyouni, K. A. M. El-Bayouki, M. F. El-Mansy, H. F. Aly, S. A. Ali, A. F. Arafa, and A. A. Haroun, “Synthesis, Structural Characterization and in Vivo anti-Diabetic Evaluation of Some New Sulfonylurea Derivatives in Normal and Silicate Coated Nanoparticle Forms as anti-Hyperglycemic Agents,” Bioorganic Chemistry 92 (2019): 103290. doi:10.1016/j.bioorg.2019.103290.
   PubMed Web of Science ®Google Scholar
• W. S. Lewis, V. Cody, N. Galitsky, J. R. Luft, W. Pangborn, S. K. Chunduru, H. T. Spencer, J. R. Appleman, and R. L. Blakley, “Methotrexate-Resistant Variants of Human Dihydrofolate Reductase with Substitutions of Leucine 22. Kinetics, Crystallography, and Potential as Selectable Markers,” The Journal of Biological Chemistry 270, no. 10 (1995): 5057–64. doi:10.1074/jbc.270.10.5057.
   PubMed Web of Science ®Google Scholar
• C. M. Richardson, D. S. Williamson, M. J. Parratt, J. Borgognoni, A. D. Cansfield, P. Dokurno, G. L. Francis, R. Howes, J. D. Moore, J. B. Murray, et al, “Triazolo[1,5-a]Pyrimidines as Novel CDK2 Inhibitors: protein Structure-Guided Design and SAR,” Bioorganic & Medicinal Chemistry Letters 16, no. 5 (2006): 1353–7. doi:10.1016/j.bmcl.2005.11.048.
   PubMed Web of Science ®Google Scholar
• J. Porter, A. Payne, B. de Candole, D. Ford, B. Hutchinson, G. Trevitt, J. Turner, C. Edwards, C. Watkins, I. Whitcombe, et al, “Tetrahydroisoquinoline Amide Substituted Phenyl Pyrazoles as Selective Bcl-2 Inhibitors,” Bioorganic & Medicinal Chemistry Letters 19, no. 1 (2009): 230–3. doi:10.1016/j.bmcl.2008.10.113.
   PubMed Web of Science ®Google Scholar
• X. Li, J. Wang, S. M. Condon, and Y. Shi, (Structure of cIAP1-BIR3 and inhibitor, 4KMN) protein data bank (2014). doi:10.2210/pdb4kmn/pdb.
   Google Scholar
• Y. Rew, D. Sun, X. Yan, H. P. Beck, J. Canon, A. Chen, J. Duquette, J. Eksterowicz, B. M. Fox, J. Fu, et al, “Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2-p53 Interaction,” Journal of Medicinal Chemistry 57, no. 24 (2014): 10499–511. doi:10.1021/jm501550p.
   PubMed Web of Science ®Google Scholar
• A. H. M. Elwahy, Journal of Chemical Research (1999). doi:10.1039/a904716f,.602-603.
   Google Scholar
• H.-S. Kim, Y.-J. Kim, H.-J. Lee, S.-Y. Kim, H. Lee, D.-S. Chang, H. Lee, H.-J. Park, and Y. Chae, “Development and Validation of Acupuncture Fear Scale,” Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–13. doi:10.1155/2013/109704.
   Web of Science ®Google Scholar
• P. L. Olive, J. P. Banáth, and R. E. Durand, “Heterogeneity in Radiation-Induced DNA Damage and Repair in Tumor and Normal Cells Measured Using the "Comet" Assay. 1990,” Radiation Research 178, no. 2 (2012): AV35–AV42. doi:10.1667/rrav04.1.
   PubMed Web of Science ®Google Scholar
• A. Collins, M. Dusinska, M. Franklin, M. Somorovska, H. Petrovska, S. Duthie, L. Fillion, M. Panayiotidis, K. Raslova, and N. Vaughan, “Comet Assay in Human Biomonitoring Studies: Reliability, Validation, and Applications,” Environmental and Molecular Mutagenesis 30, no. 2 (1997): 139–46. doi:10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• A. Yawata, M. Adachi, H. Okuda, Y. Naishiro, T. Takamura, M. Hareyama, S. Takayama, J. C. Reed, and K. Imai, “Prolonged Cell Survival Enhances Peritoneal Dissemination of Gastric Cancer Cells,” Oncogene 16, no. 20 (1998): 2681–6. doi:10.1038/sj.onc.1201792.
   PubMed Web of Science ®Google Scholar